| SCHEDULE OF INVESTMENT |
Investments
consisted of the following:
SCHEDULE OF INVESTMENT
| | |
As
of June 30,2025 | | |
As
of September 30, 2024 | |
| | |
| | |
| |
| 470,588
Common Shares of Zander Therapeutics, Inc. | |
$ | 6,495 | | |
$ | 6,495 | |
| 725,000
Series M Preferred of Zander Therapeutics, Inc. | |
| 11,238 | | |
| 11,238 | |
| | |
| | | |
| | |
| Investments,
net | |
$ | 17,733 | | |
$ | 17,333 | |
On
June 11, 2018, Regen Biopharma, Inc. was paid a property dividend consisting of 470,588 of the common shares of Zander Therapeutics,
Inc.
| Basis | | |
Fair
Value | | |
Total
Unrealized Gains/(Loss) | |
| | | | |
| | | |
| | |
| $ | 87,608 | | |
$ | 6,495 | | |
$ | (81,112 | ) |
Series
M Preferred of Zander Therapeutics, Inc.
On
November 29, 2018, the Company accepted 725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. in satisfaction of
prepaid rent and accrued interest owed to the Company collectively amounting to $13,124.
| Basis | | |
Fair
Value | | |
Total
Unrealized Gains/(Loss) | |
| | | | |
| | | |
| | |
| $ | 134,971 | | |
$ | 11,238 | | |
$ | (123,733 | ) |
On
June 30, 2025 and September 30, 2024, the Company revalued 470,588 of the common shares of Zander Therapeutics, Inc. and 725,000 shares
of the Series M Preferred stock of Zander Therapeutics, Inc. based on the following inputs:
| | |
| | |
| Fair
Value of Intellectual Property | |
$ | 300,000 | |
| Prepaid
Expenses | |
| 65,661 | |
| Due
from Employee | |
| - | |
| Note
Receivable | |
| 40000 | |
| Accrued
Interest Receivable | |
| 35,000 | |
| Investment
Securities | |
| 258,255 | |
| Convertible
Note Receivable | |
| 10,000 | |
| Accounts
Payable | |
| 30,563 | |
| Notes
Payable | |
| 400,000 | |
| Accrued
Expenses Related Parties | |
| 162,011 | |
| Notes
Payable Related Party | |
| - | |
| Accrued
Expenses | |
| 647,072 | |
| | |
| | |
| Enterprise
Value | |
| 1,948,562 | |
| | |
| | |
| Less:
Total Debt | |
| (1,239,646 | ) |
| | |
| | |
| Portion
of Enterprise Value Attributable to Shareholders | |
$ | 708,916 | |
| | |
| | |
| Fair
Value per Shares | |
$ | 0.0155 | |
|